#United States #Breast Cancer #St. Paul #Proteomics #Astrin Biosciences

Astrin Biosciences Achieves CAP Accreditation for Certitude™ Breast

Astrin Biosciences, a pioneering force in the realm of cancer detection, has recently been honored with accreditation from the College of American Pathologists (CAP). This prestigious certification comes as a result of comprehensive on-site inspections, showcasing the rigorous operational standards upheld by the company. The CAP accreditation not only validates Astrin's commitment to excellence in patient-centered diagnostics but also coincides with the introduction of Certitude™ Breast, a revolutionary non-imaging blood test able to detect early molecular signals linked to breast cancer.

The Certitude™ Breast test was unveiled at the San Antonio Breast Cancer Symposium and stands out as the first blood test of its kind. This innovative approach broadens the horizons of cancer screening beyond conventional imaging methods, allowing healthcare providers to identify potential breast cancer much earlier. It is now available by prescription in select markets across the United States, emphasizing accessibility and early intervention.

Justin Drake, the Chief Science Officer at Astrin Biosciences, expressed pride in this accomplishment, stating, "Achieving CAP accreditation, combined with our CLIA certification, signifies our unwavering commitment to the highest quality diagnostic services. These milestones are particularly significant as we advance the use of Certitude™ Breast, ensuring reliability and accuracy in every result provided to patients and healthcare practitioners."

During the CAP accreditation process, a thorough evaluation was conducted of Astrin's St. Paul laboratory, assessing key aspects such as quality control protocols, personnel qualifications, equipment, and operational safety measures. This diligent assessment guarantees that laboratories maintain the highest care standards for patients, validating the foundation upon which Astrin's innovations stand.

Astrin’s Certitude™ Breast test utilizes advanced proteomic analysis, identifying biological signals that might elude traditional screening techniques. Not only does this enhance early detection capabilities, but it also represents a shift towards a more effective approach to cancer diagnostics. CAP’s endorsement further strengthens the credibility of Astrin’s laboratory operations and its commitment to clinical excellence in supporting these groundbreaking innovations.

As the landscape of cancer detection evolves, Astrin Biosciences continues to lead with a mission centered on transforming cancer care. The integration of cutting-edge technology and stringent regulatory compliance ensures patients receive not only timely diagnostic insights but also peace of mind regarding the accuracy of their results.

For more information about Certitude™ Breast, visit Certitude Blood Test.

About Astrin Biosciences

Astrin Biosciences operates at the forefront of cancer intelligence, merging technology with clinical insight to facilitate early detection and advancement in cancer care. Their tests analyze over 9,000 proteins to detect early cancer signals often missed by standard tests. For more about Astrin Biosciences, please visit astrinbio.com.

About CAP

The College of American Pathologists (CAP) is renowned as the largest organization of certified pathologists globally, advocating for excellence in pathology and lab medicine. Their stringent accreditation process assures laboratories uphold the highest operational quality, benefiting patients and healthcare providers alike.